Please use this identifier to cite or link to this item:
Title: Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.
Authors: Hofstra, L Marije
Sauvageot, Nicolas
Albert, Jan
Alexiev, Ivailo
Garcia, Federico
Struck, Daniel
Van de Vijver, David A M C
Åsjö, Birgitta
Beshkov, Danail
Coughlan, Suzie
Descamps, Diane
Griskevicius, Algirdas
Hamouda, Osamah
Horban, Andrzej
Van Kasteren, Marjo
Kolupajeva, Tatjana
Kostrikis, Leondios G
Liitsola, Kirsi
Linka, Marek
Mor, Orna
Nielsen, Claus
Otelea, Dan
Paraskevis, Dimitrios
Paredes, Roger
Poljak, Mario
Puchhammer-Stöckl, Elisabeth
Sönnerborg, Anders
Staneková, Danica
Stanojevic, Maja
Van Laethem, Kristel
Zazzi, Maurizio
Zidovec Lepej, Snjezana
Boucher, Charles A B
Schmit, Jean-Claude
Wensing, Annemarie M J
metadata.dc.contributor.authoraffiliation: [Hofstra,LM; Sauvageot,N; Struck,D; Schmit,JC ] Luxembourg Institute of Health, Luxembourg. [Hofstra,LM; Wensing,AMJ] Department of Virology, University Medical Center Utrecht, The Netherlands. [Albert,J; Sönnerborg,A] Karolinska Institute, Solna. Karolinska University Hospital, Stockholm, Sweden. [Alexiev,I; Beshkov,D] National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria. [Garcia,F] Complejo Hospitalario Universitario de Granada. Instituto de Investigación IBS Granada, Spain. [Van de Vijver,DAMC; Boucher,CAB] Erasmus MC, University Medical Center, Rotterdam, The Netherlands. [Åsjö,B] University of Bergen, Norway. [Coughlan,S] University College Dublin, Ireland. [Descamps,D] AP-HP Groupe hospitalier Bichat-Claude Bernard. IAME INSERM UMR 1137. Université Paris Diderot Sorbonne Paris Cité, Paris, France. [Griskevicius,A] Lithuanian AIDS Center, Vilnius, Lithuania. [Hamouda,O] Robert Koch Institute, Berlin, Germany. [Horban,A] Hospital of Infectious Diseases, Warsaw, Poland. [Van Kasteren,M] St Elisabeth Hospital, Tilburg, The Netherlands. [Kolupajeva,T] Infectiology Center of Latvia, Riga. [Kostrikis,LG] University of Cyprus, Nicosia. [Liitsola,K] Department of Infectious Diseases, National Institute for Health and Welfare, Helsinki, Finland. [Linka,M] National Reference Laboratory for HIV/AIDS, National Institute of Public Health, Prague, Czech Republic. [Mor,O] National HIV Reference Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel. [Nielsen,C] Statens Serum Institut, Copenhagen, Denmark. [Otelea,D] National Institute for Infectious Diseases “Prof. dr. Matei Bals”, Bucharest, Romania. [Paraskevis,D] National Retrovirus Reference Center, University of Athens, Greece. [Paredes,R] IrsiCaixa Foundation, Badalona, Spain. [Poljak,M] Faculty of Medicine, Slovenian HIV/AIDS Reference Centre, University of Ljubljana, Slovenia. [Puchhammer-Stöckl,E] Medical University Vienna, Austria. [Staneková,D] Slovak Medical University, Bratislava, Slovakia. [Stanojevic,M] Faculty of Medicine, University of Belgrade, Serbia. [Van Laethem,K] Rega Institute for Medical Research, KU Leuven, Belgium. [Zazzi,M] University of Siena, Italy. [Zidovec Lepej,S] University Hospital for Infectious Diseases “Dr. Fran Mihaljevic”, Zagreb, Croatia. Cohorte de Adultos de la Red de Investigación en SIDA, Spain.
SPREAD Program
Keywords: HIV-1;Drug resistance;Transmission;Antiretroviral therapy;Europe;Benzoxazinas;Intervalos de confianza;Resistencia a medicamentos;Europa (Continente);Infecciones por VIH;Mutación;Prevalencia;Inhibidores de proteasas;Salud pública;Inhibidores de la transcriptasa inversa;Rilpivirina;Encuestas y Cuestionarios
metadata.dc.subject.mesh: Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Oxazines::Benzoxazines
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals
Medical Subject Headings::Geographicals::Geographic Locations::Europe
Medical Subject Headings::Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors
Medical Subject Headings::Disciplines and Occupations::Health Occupations::Medicine::Public Health
Medical Subject Headings::Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors
Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires
Issue Date: 1-Mar-2016
Publisher: Oxford University Press
Citation: Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clin. Infect. Dis. 2016; 62(5):655-63
Abstract: BACKGROUND Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. METHODS Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. RESULTS The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%-9.5%) in 2008-2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. CONCLUSIONS Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.
Description: Journal Article;
metadata.dc.identifier.doi: 10.1093/cid/civ963
ISSN: 1537-6591 (Online)
1058-4838 (Print)
Appears in Collections:01- Artículos - Complejo Hospitalario Universitario de Granada
01- Artículos - ibsGRANADA. Instituto de Investigación Biosanitaria de Granada

Files in This Item:
File Description SizeFormat 
Hofstra_TransmisionOfHIVDrugResistance.pdfArtículo publicado422,12 kBAdobe PDFView/Open
Hofstra_TransmisionOfHIVDrugResistanceSuppData.odtArchivo complementario18,8 kBOpenDocument TextView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons